Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.

Article  PubMed  Google Scholar 

Li J, Kuang XH, Zhang Y, et al. Global burden of gastric cancer in adolescents and young adults: estimates from GLOBOCAN 2020. Public Health. 2022;210:58–64.

Article  CAS  PubMed  Google Scholar 

Wu SL, Zhang Y, Fu Y, et al. Gastric cancer incidence, mortality and burden in adolescents and young adults: a time-trend analysis and comparison among China, South Korea, Japan and the USA. BMJ Open. 2022;12: e061038.

Article  PubMed  PubMed Central  Google Scholar 

Kimble DC, Lach FP, Gregg SQ, et al. A comprehensive approach to identification of pathogenic FANCA variants in Fanconi anemia patients and their families. Hum Mutat. 2018;39:237–54.

Article  CAS  PubMed  Google Scholar 

Benitez A, Liu W, Palovcak A, et al. FANCA promotes DNA double-strand break repair by catalyzing single-strand annealing and strand exchange. Mol Cell. 2018;71:621-8.e4.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Del Valle J, Rofes P, Moreno-Cabrera JM, et al. Exploring the role of mutations in Fanconi anemia genes in hereditary cancer patients. Cancers (Basel). 2020;12:829.

Article  PubMed  Google Scholar 

Ishikawa K, Ishiwatari H, Sasaki K, et al. Optimization of endoscopic ultrasound-guided tissue sample acquisition for commercially available comprehensive genome profiling. J Gastroenterol Hepatol. 2023. https://doi.org/10.1111/jgh.16304.

Article  PubMed  Google Scholar 

Nurgalieva A, Galliamova L, Ekomasova N, et al. Whole exome sequencing study suggests an impact of FANCA, CDH1 and VEGFA genes on diffuse gastric cancer development. Genes (Basel). 2023;14:280.

Article  CAS  PubMed  Google Scholar 

Nguyen B, Fong C, Luthra A, et al. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients. Cell. 2022;185:563-75.e11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pavithran K, Ajithkumar BV, Roy D, et al. Adenocarcinoma of the stomach in Fanconi’s anemia. Ann Hematol. 2002;81:666–7.

Article  CAS  PubMed  Google Scholar 

Akbari MR, Malekzadeh R, Lepage P, et al. Mutations in Fanconi anemia genes and the risk of esophageal cancer. Hum Genet. 2011;129:573–82.

Article  PubMed  Google Scholar 

Sharma P, Sharma N, Sharma D. A narrative review on Fanconi anemia: genetic and diagnostic considerations. Glob Med Genet. 2022;9:237–41.

Article  PubMed  PubMed Central  Google Scholar 

Lleo A, Wang GQ, Gershwin ME, et al. Primary biliary cholangitis. Lancet. 2020;396:1915–26.

Article  CAS  PubMed  Google Scholar 

Yin J, Liu H, Liu Z, et al. Genetic variants in Fanconi anemia pathway genes BRCA2 and FANCA predict melanoma survival. J Invest Dermatol. 2015;135:542–50.

Article  CAS  PubMed  Google Scholar 

Dai W, Zeller C, Masrour N, et al. Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer. Clin Cancer Res. 2013;19:5788–97.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barroso E, Pita G, Arias JI, et al. The Fanconi anemia family of genes and its correlation with breast cancer susceptibility and breast cancer features. Breast Cancer Res Treat. 2009;118:655–60.

Article  CAS  PubMed  Google Scholar 

Ribeiro E, Ganzinelli M, Andreis D, et al. Triple negative breast cancers have a reduced expression of DNA repair genes. PLoS ONE. 2013;8: e66243.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ganzinelli M, Mariani P, Cattaneo D, et al. Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations. Eur J Cancer. 2011;47:1086–94.

Article  CAS  PubMed  Google Scholar 

Mateo J, Porta N, Bianchini D, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21:162–74.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ciardiello F, Bang YJ, Cervantes A, et al. Efficacy and safety of maintenance therapy with pamiparib versus placebo for advanced gastric cancer responding to first-line platinum-based chemotherapy: phase 2 study results. Cancer Med. 2023;12:13145–54.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boku N, Ryu MH, Kato K, et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase II trial (ATTRACTION-4). Ann Oncol. 2019;30:250–8.

Article  CAS  PubMed  Google Scholar 

Huang JP, Lin J, Tzen CY, et al. FANCA D1359Y mutation in a patient with gastric polyposis and cancer susceptibility: a case report and review of literature. World J Gastroenterol. 2018;24:4412–8.

Article  PubMed  PubMed Central  Google Scholar 

Choi IS, Lee HS, Lee KW, et al. Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes. Med Oncol. 2011;28:991–8.

Article  CAS  PubMed  Google Scholar 

Namikawa T, Yokota K, Tanioka N, et al. Systemic inflammatory response and nutritional biomarkers as predictors of nivolumab efficacy for gastric cancer. Surg Today. 2020;50:1486–95.

Article  CAS  PubMed  Google Scholar 

Namikawa T, Shimizu S, Yokota K, et al. Isolated adrenocorticotropic hormone deficiency induced by nivolumab treatment for advanced gastric cancer. Clin J Gastroenterol. 2021;14:988–93.

Article  PubMed  Google Scholar 

Wen J, Shen H. Trend of gastric cancer incidence and death rate in adolescents and young adults: a retrospective cohort study based on the surveillance, epidemiology, and end results (SEER) database. J Gastroenterol Hepatol. 2023;38:393–403.

Article  CAS  PubMed  Google Scholar